Sei Investments Co. Reduces Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Sei Investments Co. decreased its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 3.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 37,557 shares of the biopharmaceutical company’s stock after selling 1,283 shares during the quarter. Sei Investments Co.’s holdings in TG Therapeutics were worth $668,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. XTX Topco Ltd purchased a new position in shares of TG Therapeutics during the second quarter valued at approximately $395,000. State of New Jersey Common Pension Fund D bought a new position in shares of TG Therapeutics during the 2nd quarter valued at $2,022,000. Headlands Technologies LLC bought a new position in shares of TG Therapeutics during the 2nd quarter valued at $124,000. Ashton Thomas Private Wealth LLC purchased a new position in shares of TG Therapeutics in the 2nd quarter worth $35,000. Finally, Strategic Financial Concepts LLC bought a new stake in shares of TG Therapeutics in the second quarter worth $530,000. Institutional investors own 58.58% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on TGTX shares. The Goldman Sachs Group raised their target price on TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. B. Riley raised their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $49.00 target price on shares of TG Therapeutics in a report on Wednesday, September 18th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $31.83.

TG Therapeutics Trading Up 2.5 %

Shares of NASDAQ:TGTX opened at $21.84 on Wednesday. The stock has a 50 day moving average of $22.59 and a 200 day moving average of $18.93. The company has a market cap of $3.38 billion, a PE ratio of 94.96 and a beta of 2.21. TG Therapeutics, Inc. has a 12-month low of $6.46 and a 12-month high of $26.41. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The firm had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $65.92 million. During the same period in the prior year, the company posted ($0.34) earnings per share. The company’s revenue for the quarter was up 357.0% compared to the same quarter last year. As a group, equities research analysts expect that TG Therapeutics, Inc. will post 0.13 EPS for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.